MedWatch

As raw material and energy prices rise, so do Coloplast's costs

In Tuesday’s Q1 financial results, medtech company Coloplast’s top and bottom lines reported growth, but increasing energy expenses and wage inflation in Hungary have meant that production costs have also gone up during the first quarter.

Anders Lonning-Skovgaard, EVP and CFO at Coloplast | Photo: Coloplast / PR

It is not only Coloplast’s top and bottom lines that have taken leaps in the first quarter of the skewed financial year 2021/2022.

The medtech company’s production costs also moved up a notch compared to the same period the year before, as evident in Coloplast’s financial results that were publicized on Tuesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs